Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.
about
Developments in the treatment of hemophilia B: focus on emerging gene therapyComorbidities of cardiovascular disease and cancer in hemophilia patientsLarge scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.The current state of adverse event reporting in hemophilia.The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.Comparison of physical activity and sedentary behaviours between young haemophilia A patients and healthy adolescents.The haemophilia certification system in CanadaThe cost of severe haemophilia in Europe: the CHESS study.Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles?Mild hemophilia A.Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia AMultiple Comorbid Conditions among Middle-Aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care.Participation of people with haemophilia in clinical trials of new treatments: an investigation of patients' motivations and existing barriers.Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.Adenovirus-associated virus vector-mediated gene transfer in hemophilia BSolulin increases clot stability in whole blood from humans and dogs with hemophilia.Experience of Preimplantation Genetic Diagnosis for Hemophilia at the University Hospital Virgen Del Rocío in Spain: Technical and Clinical Overview.Vascular remodeling underlies rebleeding in hemophilic arthropathyDiagnostic and therapeutic challenges of intracranial hemorrhage in neonates with congenital hemophilia: a case report and review.Prevalence, incidence, and factor concentrate usage trends of hemophiliacs in TaiwanPreclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target.Shortened Lifespan and Lethal Hemorrhage in a Hemophilia A Mouse ModelDesign of pH-Responsive Biomaterials to Enable the Oral Route of Hematological Factor IXHow I treat patients with inherited bleeding disorders who need anticoagulant therapy.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Advances and challenges in hemophilic arthropathy.Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.Prevalence and risk factors for hypertension in hemophilia.The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study.The role of disease severity in influencing body mass index in people with haemophilia: a single-institutional cross-sectional study.The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease.When von Willebrand disease comes into age - a matter of change?Clinical advances in hemophilia management.Joint protection in haemophilia.Prevalence of malignancies among U.S. male patients with haemophilia: a review of the Haemophilia Surveillance System.The aging patient with hemophilia.Haemophilia prophylaxis: how can we justify the costs?
P2860
Q26823376-8781F5F6-FEC1-43AA-BE4A-598A80090546Q28071758-45BFBE04-3F53-4A59-8C5D-A31027B7670FQ30234910-477693BF-3B76-41F8-83A5-87F70FBA768CQ30239952-DD382B4B-8CF2-41CE-97DE-5F5A5CE58AB0Q30249256-51C71A46-BDFB-4FBF-A59E-2CAD308D92C4Q30399404-A6321A52-F9F4-48A9-856B-B81C56F42C3CQ33708993-B74E6EB2-BF62-4092-9BFC-E09418DF30E7Q33750095-594769E4-C31D-4174-BC31-A3CB22F4C6A1Q33841435-983AC7CB-D976-4B51-A4F4-7918E6DB60CCQ34045763-B45153B3-9F72-407A-967B-4D67653DB653Q34157427-631E9303-2E2D-4373-9D4C-464CEA170C51Q34614695-BBC68BD4-0D1A-4FF6-9C26-07642E21DC7FQ35069871-A53D901E-A685-4DD2-91F7-6D3648641A96Q35100303-BBBEA6B6-8BA4-436B-875B-6A5F8D8ECE6EQ35200471-BBE32624-834D-457F-996D-EDBB5A518509Q35265322-E7CD970B-9A2B-4F48-8F61-389FE5AFD714Q35311771-A1CCAEA5-B3B5-41A0-8F89-7FDE7372B3ACQ35691659-420C880F-993E-48DB-88E7-E6612AD9FB42Q35885322-5FE3921D-FDE9-4905-B9C3-6093424539C8Q35901481-B5F8664F-5D6A-453B-9B9A-8EC1CB090BE0Q36199877-6879B21F-7AC6-474C-A5EB-B58234A0A7ADQ36250900-2FD71A9B-ECB3-471F-86F1-783496D0F61FQ36463984-9DB7F795-4C13-4E04-8107-D3A8DFE606F3Q36648875-6A3B2B3E-442F-4E32-A560-EF6B84432DB8Q36868829-3BE22D66-7E0A-425C-B0DF-E66904D9A5C9Q36936276-4A1E46FC-3014-49D0-9E5C-76446AF72940Q37097089-84509656-2F4F-4362-BCEC-0C9AB8F21424Q37230340-B2B8BBDD-4F98-47EC-A17C-E72C6694A95CQ37279529-5B2BB2FC-C31A-4F88-9FDF-D512FFF6D0C2Q37325682-23C37070-0DAE-4BF5-90FB-72600DEE0678Q37363589-382F4405-00B7-4DDF-9E92-D2421BA150A6Q37443624-53793326-B660-430D-B117-75689B73550EQ37621263-EA32B58D-DF6B-4FAF-A1DC-0D4B65DEFC6DQ37720804-A79CD8E4-5695-47AF-9FB6-6C45E94C6238Q37854842-BFD118D2-C058-4453-99E5-B3DE359D2D4DQ37900933-8706F69B-F030-4496-A281-47104BB6E263Q37912258-5B4F7B30-D323-4DD0-AD4D-388B4CDE03D8Q37973876-67848EBF-E33A-4B3E-B1B6-1F542DD8C08DQ37995101-215BC6D9-9213-4918-8CD8-4026440F55FDQ38002994-80FED94A-7C2A-4119-B7BA-42236388F2F3
P2860
Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Mortality rates, life expectan ...... ho were not infected with HIV.
@en
Mortality rates, life expectan ...... ho were not infected with HIV.
@nl
type
label
Mortality rates, life expectan ...... ho were not infected with HIV.
@en
Mortality rates, life expectan ...... ho were not infected with HIV.
@nl
prefLabel
Mortality rates, life expectan ...... ho were not infected with HIV.
@en
Mortality rates, life expectan ...... ho were not infected with HIV.
@nl
P2093
P921
P1433
P1476
Mortality rates, life expectan ...... ho were not infected with HIV.
@en
P2093
Charles R M Hay
Christine A Lee
Christopher A Ludlam
Frank G H Hill
Michael Williams
Paul L F Giangrande
Rosemary J Spooner
Sarah C Darby
Sau Wan Kan
P304
P356
10.1182/BLOOD-2006-10-050435
P407
P577
2007-04-19T00:00:00Z